<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956524</url>
  </required_header>
  <id_info>
    <org_study_id>UTCV_101</org_study_id>
    <nct_id>NCT03956524</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults</brief_title>
  <official_title>An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of EuTCV, in comparison
      to TCV (Typbar-TCV™, Bharat Biotech) and Vi-Polysaccharide vaccine (Typhim Vi®, Sanofi
      Pasteur) in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2019</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy adult volunteers will be randomized in a 1:1:1 ratio to receive single dose of test or the comparator vaccines.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic solicited adverse events</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with seroconversion</measure>
    <time_frame>Baseline to Day 42</time_frame>
    <description>Defined as a 4-fold or more rise in anti-Vi antibody titers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of EuTCV will be administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Typbar-TCV™ will be administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Typhim Vi® will be administered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EuTCV</intervention_name>
    <description>Single 0.5 mL dose of TCV of EuBiologics co., Ltd.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typbar-TCV™</intervention_name>
    <description>Single 0.5 mL dose of TCV of Bharat Biotech</description>
    <arm_group_label>Comparator group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typhim Vi®</intervention_name>
    <description>Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur</description>
    <arm_group_label>Comparator group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between and including 18 and 45 years at time of Visit 1

          2. Subjects willing to give written informed consent to participate in the trial

          3. Subjects who are healthy as determined by medical history, with no clinically
             significant abnormalities in clinical examination and laboratory tests

        Exclusion Criteria:

          1. Subjects unwilling to give his/her consent to participate in the trial

          2. Subjects who have received Typhoid containing vaccines

          3. Subjects who have past history of Typhoid

          4. Subjects already immunized with any licensed vaccine within 4 weeks

          5. Subjects with known hypersensitivity to any component of the study vaccine

          6. Subjects who are pregnant, lactating or childbearing age not using a reliable method
             of contraception

          7. Subjects with any abnormality or chronic disease

          8. Subjects with evidence of acute illness within past 7 days requiring systemic
             antibiotic or antiviral therapy

          9. Subjects who have experienced transient thrombocytopenia or neurological complications
             following an earlier immunization against diphtheria and/or typhoid

         10. Subjects who have known history of immune function disorders

         11. Subjects who have known history of administration of blood or blood-derived products

         12. Subjects who have history of alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

